C12N 2760/18034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/18034 (Use of virus or viral component as vaccine) appears on 80 US grants and 109 published applications in this corpus.
Search patents in C12N- Granted patents
- 80
- Published applications
- 109
- Assignees
- 57
- Inventors
- 173
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 2 | 0 |
| 2004 | 0 | 2 |
| 2005 | 1 | 2 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 2 |
| 2009 | 2 | 2 |
| 2010 | 1 | 4 |
| 2011 | 1 | 1 |
| 2012 | 0 | 2 |
| 2013 | 0 | 5 |
| 2014 | 2 | 7 |
| 2015 | 2 | 7 |
| 2016 | 9 | 6 |
| 2017 | 8 | 10 |
| 2018 | 4 | 2 |
| 2019 | 6 | 6 |
| 2020 | 6 | 11 |
| 2021 | 7 | 7 |
| 2022 | 8 | 9 |
| 2023 | 4 | 3 |
| 2024 | 3 | 8 |
| 2025 | 9 | 8 |
| 2026 | 5 | 5 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Mumps and measles virus immunogens and their use26 May 2026US 12,636,360 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Betacoronavirus mRNA vaccines19 May 2026US 12,629,412 B2ModernaTX, Inc.
- Paramyxovirus virus-like particles as protein delivery vehicles14 Apr 2026US 12,600,956 B2The Penn State Research Foundation
- Betacoronavirus mRNA vaccines17 Feb 2026US 12,551,734 B2ModernaTX, Inc.
- Betacoronavirus RNA vaccines13 Jan 2026US 12,521,577 B2ModernaTX, Inc.
- Mumps and measles virus immunogens and their use20 Aug 2026US 2026/0240984 A1The United States of America, as represented by the Secretary, Department of Health and Human Ser.
- Virus attenuation30 Apr 2026US 2026/0115273 A1University of Lancaster
- Betacoronavirus mrna vaccines23 Apr 2026US 2026/0108595 A1ModernaTX, Inc.
- Betacoronavirus mrna vaccines9 Apr 2026US 2026/0097110 A1ModernaTX, Inc.
- Rsv virus-like particles and methods of use thereof1 Jan 2026US 2026/0000750 A1Children's Healthcare of Atlanta, Inc.
Most cited
By later US patents
- Combination PIV3/hMPV RNA vaccines110US 10,064,934 B2ModernaTX, Inc. · 2018
- Betacoronavirus mRNA vaccine46US 10,702,600 B1ModernaTX, Inc. · 2020
- Methods and interferon deficient substrates for the propagation of viruses37US 6,852,522 B1Mount Sinai School of Medicine of New York University · 2005
- Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals35US 6,669,943 B1Mount Sinai School of Medicine of New York University · 2003
- Methods and interferon deficient substrates for the propagation of viruses34US 6,573,079 B1Mount Sinai School of Medicine of New York University · 2003